Ending a decades-long wait, the US Food and Drug Administration (FDA) today approved the Amplatzer PFO Occluder device (St. Jude Medical) for recurrent stroke prevention in patients with a patent ...

Presentation of neurological data confirms patients in the device group had fewer, smaller strokes that were less likely to originate from blood clots passing through the PFO "Data from the RESPECT ...

St. Jude Medical’s stroke-fighting heart occluder picked up FDA approval on Friday. The device had previously been available in the U.S. under a humanitarian device exemption, but was voluntarily ...

Two controversial trials testing PFO closure with the Amplatzer PFO Occluder (St. Jude Medical) in patients with cryptogenic stroke, first presented last fall at the TCT meeting, have now been ...

MINNEAPOLIS, Minnesota — The now publicly held AGA Medical has won Chinese approval for three of its devices and will begin selling there through its distributor, Abbott Laboratories. A broader ...

“Percutaneous PFO closure with the investigational Amplatzer PFO Occluder device for secondary prevention of thromboembolism showed no significant reduction in ischemic and bleeding events compared ...

Please provide your email address to receive an email when new articles are posted on . St. Jude Medical announced the FDA approved its transcatheter device for occlusion of patent foramen ovale. The ...

A group of doctors convened by the Food and Drug Administration decided Tuesday that a new St. Jude Medical heart device to prevent strokes appears safe and effective, after more than 13 years of U.S.

Please provide your email address to receive an email when new articles are posted on . Patent foramen ovale closure appears to be superior to medical management in preventing the recurrence of ...

MIAMI – The Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) and PC Trial were both presented last week at TCT 2012 after ...